ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

IDH Immunodiagnostic Systems Holdings Plc

378.00
0.00 (0.00%)
10 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Immunodiagnostic Systems Holdings Plc LSE:IDH London Ordinary Share GB00B01YZ052 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 378.00 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Immunodiagnostic Systems Hldgs PLC Launch of IDS-iSYS Total Testosterone assay (8864M)

19/10/2016 7:00am

UK Regulatory


Immunodiagnostic Systems (LSE:IDH)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Immunodiagnostic Systems Charts.

TIDMIDH

RNS Number : 8864M

Immunodiagnostic Systems Hldgs PLC

19 October 2016

Immunodiagnostic Systems Holdings plc.

19 October 2016

Launch of IDS-iSYS Total Testosterone assay - new assay in the IDS fertility portfolio

Immunodiagnostic Systems Holdings plc (IDS), a specialist producer of manual and automated diagnostic testing kits and instruments for the clinical market, has launched the IDS-iSYS Total Testosterone assay in the European market. This is a fully automated CLIA assay for use with serum and plasma samples on the IDS-iSYS Automated System.

The launch of the IDS-iSYS Total Testosterone assay is the second product released as part of the emerging fertility (steroid hormones) portfolio following the launch of the IDS-iSYS 17-OH Progesterone assay in May 2016.

The IDS-iSYS Total Testosterone assay quantitatively measures a patient's Testosterone level and offers clinicians an easy, non-invasive way to diagnose and treat disorders involving the male sex hormones (androgens).

The global market for testosterone tests has been valued at around $110 million per year.

For further information:

   Immunodiagnostic Systems Holdings plc                   Tel: +44 (0) 191 519 0660 

Patricio Lacalle, Chief Executive Officer

Paul Martin, Group Finance Director

Peel Hunt LLP Tel: +44 (0) 20 7418 8900

James Steel

Oliver Jackson

This information is provided by RNS

The company news service from the London Stock Exchange

END

PRLFFWFWAFMSEES

(END) Dow Jones Newswires

October 19, 2016 02:00 ET (06:00 GMT)

1 Year Immunodiagnostic Systems Chart

1 Year Immunodiagnostic Systems Chart

1 Month Immunodiagnostic Systems Chart

1 Month Immunodiagnostic Systems Chart

Your Recent History

Delayed Upgrade Clock